(Q28284851)

9

object named as

P S Sørensen

0 references

author name string

F Sellebjerg

1

0 references

D Barnes

2

0 references

G Filippini

3

0 references

R Midgard

4

0 references

X Montalban

5

0 references

P Rieckmann

6

0 references

K Selmaj

7

0 references

L H Visser

European Journal of Neurology

8

0 references

language of work or name

English

0 references

publication date

December 2005

0 references

published in

0 references

volume

12

0 references

issue

12

0 references

page(s)

939-46

0 references

1 reference

https://api.crossref.org/works/10.1111/J.1468-1331.2005.01352.X

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

20 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

Multiple sclerosis: management issues during pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

A transcranial magnetic stimulation study evaluating methylprednisolone treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

Effect of relapses on development of residual deficit in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

Plasma exchange for severe optic neuritis: treatment of 10 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

Gadolinium-enhanced magnetic resonance imaging predicts response to methylprednisolone in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X

Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01352.X